Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulipristal Acetate for Abnormal Uterine Bleeding Associated With Leiomyomas
NCT02147158Phase 3Completed
- Sponsor
- Allergan
- Start
- Jan 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ulipristal in Uterine Fibroids (UF) (6 arms), sponsored by Allergan. Primary endpoints: Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment in Treatment Course 1 and Time to Absence of Bleeding on Treatment During Treatment Course 1. Started Jan 2014; status: completed.
02
Drugs
ulipristal
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT02147158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02147158.